Former Novartis exec joins Ethris as CMO

4 June 2019

Germany’s Ethris, a leader in mRNA-based therapeutics, is expanding its leadership team by the addition of Thomas Langenickel in the role of chief medical officer.

Dr Langenickel joins Ethris from Swiss pharma giant Novartis (NOVN: VX), where he was executive director and head of respiratory profiling within the Translational Medicine Group.

“Thomas has a wealth of experience in guiding novel programs from discovery research into clinical development and beyond,” stated Gita Dittmar, chief executive of Ethris. “His leadership in translational medicine and deep experience in respiratory and cardiovascular disease indications make him a perfect fit for Ethris as we transition our lead program ETH42 for development activities,” he noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK